Incannex's IHL-42X Lowered AHI, ODI in Obstructive Sleep Apnea Phase 2 Trial
The clinical trial assessed three doses of IHL-42X at reducing the AHI in patients with OSA, as well as collected safety data.
Mark Bleackley Incannex Healthcare Ltd Drug Administration Western Australia Centre Sleep Science Oxygen Desaturation
Source: sleepreviewmag.com